BACKGROUND: Evolutionarily conserved genes and their associated molecular pathways can serve as a translational bridge between human and mouse research, extending our understanding of biological pathways mediating individual differences in behavior and risk for psychopathology. METHODS: Comparative gene array analysis in the amygdala and cingulate cortex between the serotonin transporter knockout mouse, a genetic animal model replicating features of human depression, and existing brain transcriptome data from postmortem tissue derived from clinically depressed humans was conducted to identify genes with similar changes across species (i.e., conserved) that may help explain risk of depressive-like phenotypes. Human neuroimaging analysis was then used to investigate the impact of a common single-nucleotide polymorphism (rs1064448) in a gene with identified conserved human-mouse changes, adenylate cyclase 7 (ADCY7), on threat-associated amygdala reactivity in two large independent samples. RESULTS: Comparative analysis identified genes with conserved transcript changes in amygdala (n = 29) and cingulate cortex (n = 19), both critically involved in the generation and regulation of emotion. Selected results were confirmed by real-time quantitative polymerase chain reaction, including upregulation in the amygdala of transcripts for ADCY7, a gene previously implicated in human depression and associated with altered emotional responsiveness in mouse models. Translating these results back to living healthy human subjects, we show that genetic variation (rs1064448) in ADCY7 biases threat-related amygdala reactivity. CONCLUSIONS: This converging cross-species evidence implicates ADCY7 in the modulation of mood regulatory neural mechanisms and, possibly, risk for and pathophysiology of depression, together supporting a continuous dimensional approach to major depressive disorder and other affective disorders. Copyright Â
BACKGROUND: Evolutionarily conserved genes and their associated molecular pathways can serve as a translational bridge between human and mouse research, extending our understanding of biological pathways mediating individual differences in behavior and risk for psychopathology. METHODS: Comparative gene array analysis in the amygdala and cingulate cortex between the serotonin transporter knockout mouse, a genetic animal model replicating features of humandepression, and existing brain transcriptome data from postmortem tissue derived from clinically depressed humans was conducted to identify genes with similar changes across species (i.e., conserved) that may help explain risk of depressive-like phenotypes. Human neuroimaging analysis was then used to investigate the impact of a common single-nucleotide polymorphism (rs1064448) in a gene with identified conserved human-mouse changes, adenylate cyclase 7 (ADCY7), on threat-associated amygdala reactivity in two large independent samples. RESULTS: Comparative analysis identified genes with conserved transcript changes in amygdala (n = 29) and cingulate cortex (n = 19), both critically involved in the generation and regulation of emotion. Selected results were confirmed by real-time quantitative polymerase chain reaction, including upregulation in the amygdala of transcripts for ADCY7, a gene previously implicated in humandepression and associated with altered emotional responsiveness in mouse models. Translating these results back to living healthy human subjects, we show that genetic variation (rs1064448) in ADCY7 biases threat-related amygdala reactivity. CONCLUSIONS: This converging cross-species evidence implicates ADCY7 in the modulation of mood regulatory neural mechanisms and, possibly, risk for and pathophysiology of depression, together supporting a continuous dimensional approach to major depressive disorder and other affective disorders. Copyright Â
Authors: Greg J Siegle; Stuart R Steinhauer; Michael E Thase; V Andrew Stenger; Cameron S Carter Journal: Biol Psychiatry Date: 2002-05-01 Impact factor: 13.382
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: Greg J Siegle; Wesley Thompson; Cameron S Carter; Stuart R Steinhauer; Michael E Thase Journal: Biol Psychiatry Date: 2006-10-06 Impact factor: 13.382
Authors: Christopher S Monk; Rachel G Klein; Eva H Telzer; Elizabeth A Schroth; Salvatore Mannuzza; John L Moulton; Mary Guardino; Carrie L Masten; Erin B McClure-Tone; Stephen Fromm; R James Blair; Daniel S Pine; Monique Ernst Journal: Am J Psychiatry Date: 2007-11-06 Impact factor: 18.112
Authors: D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari Journal: Neuroimage Date: 2004-05 Impact factor: 6.556
Authors: Eric Fakra; Luke W Hyde; Adam Gorka; Patrick M Fisher; Karen E Muñoz; Mark Kimak; Indrani Halder; Robert E Ferrell; Stephen B Manuck; Ahmad R Hariri Journal: Arch Gen Psychiatry Date: 2009-01
Authors: Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert Journal: Pharmacol Rev Date: 2017-04 Impact factor: 25.468
Authors: Jeanne E Savage; Chelsea Sawyers; Roxann Roberson-Nay; John M Hettema Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-05-19 Impact factor: 3.568
Authors: Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom Journal: Physiol Rev Date: 2021-10-26 Impact factor: 37.312
Authors: Sloane K Tilley; Elizabeth M Martin; Lisa Smeester; Robert M Joseph; Karl C K Kuban; Tim C Heeren; Olaf U Dammann; T Michael O'Shea; Rebecca C Fry Journal: PLoS One Date: 2018-03-07 Impact factor: 3.240
Authors: L K Zhuang; G P Xu; X R Pan; Y J Lou; Q P Zou; D Xia; W W Yan; Y T Zhang; P M Jia; J H Tong Journal: Cell Death Dis Date: 2014-04-10 Impact factor: 8.469